

**Table 1.1 Therapeutic monoclonal antibodies, Fc fusion and Fab conjugates approved or in review in the European Union or United States<sup>a</sup>—cont'd**

Brand name	Molecule	Type of mAb	Year approved	Company	Indication	Administration route
MyoScint	Imciromab pentetate	Anti-human cardiac myosin; murine mAb fragment labeled with indium-111	(1996)	Centocor	Myocardial infarction imaging agent	IV
Nplate	Romiplostim	Fc peptide fusion. This molecule contains two identical single-chain subunits, each consisting of human immunoglobulin IgG1 Fc domain, covalently linked at the C-terminus to a peptide containing two thrombopoietin receptor-binding domains	(2008)	Amgen	Chronic idiopathic (immune) thrombocytopenic purpura (ITP)	SC
NeutroSpec	Fanolesomab	Anti-CD15; murine mAb labeled with technetium-99	(2004)	Palatin-Technologies	Imaging of equivocal appendicitis	IV
OncoScint	Satumomab pentetide	Anti-TAG72 (tumor-associated glycoprotein; murine IgG1κ conjugated to GYK-DTPA	1992 (1992)	Cytogen	Imaging agent for colorectal and ovarian cancer	IV injection
Opdivo	Nivolumab	Anti-PD1 antibody. The molecule is a human IgG4 κ immunoglobulin	2014	Bristol-Myers Squibb	Treatment for patients with unresectable (cannot be removed by surgery) or metastatic (advanced) melanoma who no longer respond to other drugs	IV